Testing effectiveness (Phase 2)WithdrawnNCT03881735
What this trial is testing
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Who this might be right for
Blasts Under 5 Percent of Peripheral Blood White CellsBone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment LevelIDH2 Gene Mutation+2 more
Roswell Park Cancer Institute